179 results on '"Sprague SM"'
Search Results
2. Renal bone disease.
- Author
-
Sprague SM and Sprague, Stuart M
- Published
- 2010
- Full Text
- View/download PDF
3. KDOQI US commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD).
- Author
-
Uhlig K, Berns JS, Kestenbaum B, Kumar R, Leonard MB, Martin KJ, Sprague SM, Goldfarb S, Uhlig, Katrin, Berns, Jeffrey S, Kestenbaum, Bryan, Kumar, Raj, Leonard, Mary B, Martin, Kevin J, Sprague, Stuart M, and Goldfarb, Stanley
- Abstract
This commentary provides a US perspective on the 2009 KDIGO (Kidney Disease: Improving Global Outcomes) Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). KDIGO is an independent international organization with the primary mission of the promotion, coordination, collaboration, and integration of initiatives to develop and implement clinical practice guidelines for the care of patients with kidney disease. The National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (KDOQI), recognizing that international guidelines need to be adapted for each country, convened a group of experts to comment on the application and implementation of the KDIGO guideline for patients with CKD in the United States. This commentary puts the KDIGO guideline into the context of the supporting evidence and the setting of care delivered in the United States and summarizes important differences between prior KDOQI guidelines and the newer KDIGO guideline. It also considers the potential impact of a new bundled payment system for dialysis clinics. The KDIGO guideline addresses the evaluation and treatment of abnormalities of CKD-MBD in adults and children with CKD stages 3-5 on long-term dialysis therapy or with a kidney transplant. Tests considered are those that relate to laboratory, bone, and cardiovascular abnormality detection and monitoring. Treatments considered are interventions to treat hyperphosphatemia, hyperparathyroidism, and bone disease in patients with CKD stages 3-5D and 1-5T. Limitations of the evidence are discussed. The lack of definitive clinical outcome trials explains why most recommendations are not of level 1 but of level 2 strength, which means weak or discretionary recommendations. Suggestions for future research highlight priority areas. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
4. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate.
- Author
-
Sprague SM and Sprague, Stuart M
- Abstract
Background: Obstacles to successful management of hyperphosphatemia in chronic kidney disease include inadequate control of dietary phosphate and non-compliance with phosphate-binder therapy. Three major classes of phosphate binders include calcium-based binders, sevelamer HCl, and lanthanum carbonate.Scope: A literature search was performed using MEDLINE and EMBASE databases to identify clinical trials from January 1966 to May 2007 comparing classes of phosphate binders with regard to efficacy, safety, compliance, or pharmacoeconomics. Search terms included lanthanum AND sevelamer, lanthanum AND calcium, and sevelamer AND calcium. A total of 1372 articles were identified in the search, with 125 review articles and clinical trials of interest identified.Findings: Calcium-based binders are effective, but their potential to contribute to total body calcium overload and vascular calcification is an important long-term clinical concern. Sevelamer HCl is effective in reducing serum phosphate, has no systemic absorption, and does not increase total body calcium load. However, sevelamer HCl binds bile acids, is not an efficient phosphate binder in an acidic environment, and contributes to metabolic acidosis. Lanthanum carbonate is a potent and selective phosphate binder that retains high affinity for phosphate over a wide pH range, does not bind bile acids or contribute to metabolic acidosis, and has the potential to reduce pill burden and increase patient compliance compared with other phosphate binders.Conclusions: All three classes of phosphate binders are effective at reducing serum phosphate levels. Lanthanum carbonate may result in increased adherence by decreasing the pill burden. [ABSTRACT FROM AUTHOR]- Published
- 2007
- Full Text
- View/download PDF
5. Renal function and risk of hip and vertebral fractures in older women: is it always osteoporosis?
- Author
-
Sprague SM
- Published
- 2007
- Full Text
- View/download PDF
6. The role of calcimimetics in chronic kidney disease.
- Author
-
Gal-Moscovici A and Sprague SM
- Published
- 2006
- Full Text
- View/download PDF
7. Beta2-microglobulin stimulates osteoclast formation.
- Author
-
Menaa C, Esser E, Sprague SM, Menaa, C, Esser, E, and Sprague, S M
- Abstract
Dialysis-related amyloidosis is a complication of long-term chronic kidney disease (CKD) resulting in deposition of beta(2)-microglobulin (beta(2)M) amyloid in osteoarticular tissue. Clinical manifestations include destructive arthropathy, bone cysts, and fractures. Since osteolytic lesions are prominent findings around the beta(2)M deposits, we sought evidence whether beta(2)M causes bone destruction by directly stimulating osteoclast activity and if this was mediated by local cytokine production. A dose-dependent increase in the number of tartrate-resistant alkaline phosphatase-positive multinucleated cells was found in cultured mouse marrow cells treated with beta(2)M. Osteoprotegerin was unable to block this osteoclastogenic effect of beta(2)M. Osteoblasts or stromal cells were not necessary to induce this osteoclastogenesis, as formation was induced by incubating beta(2)M with colony-forming unit granulocyte macrophages (the earliest identified precursor of osteoclasts) or the murine RAW 264.7 monocytic cell line. beta(2)M Upregulated tumor necrosis factor-alpha (TNF-alpha) and IL-1 expression in a dose-dependent manner; however, a TNF-alpha-neutralizing antibody blocked beta(2)M-induced osteoclast formation. These results show that beta(2)M stimulates osteoclastogenesis, supporting its direct role in causing bone destruction in patients with CKD. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
8. Sustained Reduction of Elevated Intact Parathyroid Hormone Concentrations with Extended-release Calcifediol Slows Chronic Kidney Disease Progression in Secondary Hyperparathyroidism Patients.
- Author
-
Bishop CW, Ashfaq A, Strugnell SA, Choe J, Patel N, Norris KC, and Sprague SM
- Abstract
Introduction: Chronic kidney disease (CKD) drives onerous human and healthcare costs, underscoring an urgent need to avert disease progression. Secondary hyperparathyroidism (SHPT) develops as CKD advances, and persistently elevated parathyroid hormone (PTH) may be nephrotoxic and associated with earlier dialysis onset. This study examines, for the first time, the hypothesis that sustained reduction of elevated intact PTH (iPTH) with extended-release calcifediol (ERC) reduces the nephrotoxic impact of SHPT and forestalls renal decline., Methods: Changes in estimated glomerular filtration rate (eGFR) were analyzed post-hoc in 126 adults with SHPT, stage 3-4 CKD and low serum 25-hydroxyvitamin D (25D) treated for one year with ERC in pivotal trials. ERC was administered at 30 μg/day increasing, as needed, to 60 μg/day to achieve ≥30% reductions in iPTH. Calcium, phosphorus, 25D, 1,25-dihydroxyvitamin D (1,25D), iPTH, eGFR, fibroblast growth factor 23 (FGF23), bone turnover markers (BTM), and urine albumin-to-creatinine ratio (uACR) were measured at baseline (BL) and regular intervals. Participants were categorized by achievement (or not) of sustained ≥30% iPTH reductions over the last 2 quarters of treatment to evaluate differences in eGFR decline., Results: For all participants, 25D increased 58.5±2.3 (SE) ng/mL (p<0.001) by the end of treatment (EOT), 1,25D increased 10.1±1.8 pg/mL (p<0.001), iPTH decreased from 143.8±5.8 pg/mL to 108.8±7.2 (p<0.001), BTMs improved (p<0.01) and eGFR declined 2.2±0.5 mL/min/1.73m2 (p<0.001). The rate of eGFR decline was >5-fold higher (p=0.014) in participants who did not achieve sustained iPTH reductions of ≥30% (3.2±0.7; 12.7±2.2%) than in those who did (0.6±0.8; 2.9±2.4%). It was highest in the 30 participants who did not exhibit an iPTH lowering response in both of the last 2 quarters of treatment (5.4±0.9; 20.9±3.4%). Duration of iPTH reduction had no impact on safety parameters. Degree of iPTH reduction at EOT was also associated with slower CKD progression., Conclusion: Sustained reduction of elevated iPTH with ERC treatment was associated with slower rates of eGFR decline in patients with SHPT and stage 3-4 CKD without raising safety concerns. A prospective trial is warranted to confirm this finding., (The Author(s). Published by S. Karger AG, Basel.)
- Published
- 2024
- Full Text
- View/download PDF
9. Effectiveness of tenapanor for treating hyperphosphatemia in patients receiving dialysis: a plain language summary of the OPTIMIZE study.
- Author
-
Sprague SM, Edelstein S, Spiegel DM, Rosenbaum DP, Thomas C, and Weiner DE
- Subjects
- Humans, Sulfonamides therapeutic use, Sulfonamides adverse effects, Hyperphosphatemia etiology, Hyperphosphatemia drug therapy, Renal Dialysis adverse effects
- Published
- 2024
- Full Text
- View/download PDF
10. Tenapanor: A Phosphate Absorption Inhibitor for the Management of Hyperphosphatemia in Patients With Kidney Failure.
- Author
-
Hill Gallant KM, Sprague SM, Rosenbaum DP, Spiegel DM, Kozuka K, Edelstein S, and Chertow GM
- Abstract
Because of increased risks of cardiovascular disease and death, patients with hyperphosphatemia receiving maintenance dialysis are advised to limit phosphorus consumption and are prescribed phosphate binders in an effort to better control serum phosphate concentrations. Because of large pill size, pill burden, and tolerability issues, phosphate binder adherence is relatively poor. On ingestion, phosphate is absorbed from the intestine via transcellular or paracellular transport. Data show that inhibiting sodium-hydrogen exchanger 3 modulates paracellular phosphate absorption (the predominant pathway in humans). Tenapanor is a first-in-class, minimally absorbed, phosphate absorption inhibitor that selectively inhibits sodium-hydrogen exchanger 3, with a mechanism distinct from, and complementary to, that of phosphate binders. In phase 3 and postregistrational studies, tenapanor conferred statistically significant and clinically meaningful reductions in serum phosphate in patients receiving maintenance dialysis with hyperphosphatemia. Here, we review the available preclinical and clinical data on the effects of tenapanor on controlling intestinal phosphate absorption., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
11. Associations of Kidney Functional Magnetic Resonance Imaging Biomarkers with Markers of Inflammation in Individuals with CKD.
- Author
-
Trujillo J, Alotaibi M, Seif N, Cai X, Larive B, Gassman J, Raphael KL, Cheung AK, Raj DS, Fried LF, Sprague SM, Block G, Chonchol M, Middleton JP, Wolf M, Ix JH, Prasad P, Isakova T, and Srivastava A
- Subjects
- Humans, Female, Male, Middle Aged, Adult, Magnetic Resonance Imaging methods, Biomarkers blood, Renal Insufficiency, Chronic diagnostic imaging, Renal Insufficiency, Chronic complications, Inflammation diagnostic imaging, Kidney diagnostic imaging, Kidney physiopathology, Kidney pathology
- Published
- 2024
- Full Text
- View/download PDF
12. Tenapanor as Therapy for Hyperphosphatemia in Maintenance Dialysis Patients: Results from the OPTIMIZE Study.
- Author
-
Sprague SM, Weiner DE, Tietjen DP, Pergola PE, Fishbane S, Block GA, Silva AL, Fadem SZ, Lynn RI, Fadda G, Pagliaro L, Zhao S, Edelstein S, Spiegel DM, and Rosenbaum DP
- Subjects
- Female, Humans, Male, Middle Aged, Isoquinolines therapeutic use, Sulfonamides therapeutic use, Treatment Outcome, Hyperphosphatemia etiology, Hyperphosphatemia therapy, Renal Dialysis adverse effects
- Published
- 2024
- Full Text
- View/download PDF
13. Functional regulation of microglia by vitamin B12 alleviates ischemic stroke-induced neuroinflammation in mice.
- Author
-
Ge Y, Yang C, Zadeh M, Sprague SM, Lin YD, Jain HS, Determann BF 2nd, Roth WH, Palavicini JP, Larochelle J, Candelario-Jalil E, and Mohamadzadeh M
- Abstract
Ischemic stroke is the second leading cause of death and disability worldwide, and efforts to prevent stroke, mitigate secondary neurological damage, and promote neurological recovery remain paramount. Recent findings highlight the critical importance of microbiome-related metabolites, including vitamin B12 (VB12), in alleviating toxic stroke-associated neuroinflammation. Here, we showed that VB12 tonically programmed genes supporting microglial cell division and activation and critically controlled cellular fatty acid metabolism in homeostasis. Intriguingly, VB12 promoted mitochondrial transcriptional and metabolic activities and significantly restricted stroke-associated gene alterations in microglia. Furthermore, VB12 differentially altered the functions of microglial subsets during the acute phase of ischemic stroke, resulting in reduced brain damage and improved neurological function. Pharmacological depletion of microglia before ischemic stroke abolished VB12-mediated neurological improvement. Thus, our preclinical studies highlight the relevance of VB12 in the functional programming of microglia to alleviate neuroinflammation, minimize ischemic injury, and improve host neurological recovery after ischemic stroke., Competing Interests: The authors declare no competing interests., (© 2024 The Authors.)
- Published
- 2024
- Full Text
- View/download PDF
14. Serum Phosphorus Management with Sucroferric Oxyhydroxide as a First-Line Phosphate Binder within the First Year of Hemodialysis.
- Author
-
Medaura JA, Zhou M, Ficociello LH, Anger MS, and Sprague SM
- Subjects
- Adult, Humans, Retrospective Studies, Renal Dialysis adverse effects, Renal Dialysis methods, Ferric Compounds therapeutic use, Sucrose, Phosphates, Drug Combinations, Phosphorus, Hyperphosphatemia drug therapy, Hyperphosphatemia etiology
- Abstract
Introduction: Sucroferric oxyhydroxide (SO), a non-calcium, chewable, iron-based phosphate binder (PB), effectively lowers serum phosphorus (sP) concentrations while reducing pill burden relative to other PBs. To date, SO studies have largely examined treatment-experienced, prevalent hemodialysis populations. We aimed to explore the role of first-line SO initiated during the first year of dialysis., Methods: We retrospectively analyzed deidentified data from adults receiving in-center hemodialysis who were prescribed SO monotherapy within the first year of hemodialysis as part of routine clinical care. All patients continuing SO monotherapy for 12 months were included. Changes from baseline in sP, achievement of sP ≤5.5 and ≤4.5 mg/dL, and other laboratory parameters were analyzed quarterly for 1 year., Results: The overall cohort included 596 patients, 286 of whom had a dialysis vintage ≤3 months. In the 3 months preceding SO initiation, sP rapidly increased (mean increases of 1.02 and 1.65 mg/dL in the overall cohort and incident cohort, respectively). SO treatment was associated with significant decreases in quarterly sP (mean decreases of 0.26-0.36; p < 0.0001 for each quarter and overall). While receiving SO, 55-60% of patients achieved sP ≤5.5 mg/dL and 21-24% achieved sP ≤4.5 mg/dL (p < 0.0001 for each quarter and overall vs. baseline). Daily PB pill burden was approximately 4 pills. Serum calcium concentrations increased and intact parathyroid hormone concentrations decreased during SO treatment (p < 0.0001 vs. baseline)., Conclusions: Among patients on hemodialysis, initiating SO as a first-line PB resulted in significant reductions in sP while maintaining a relatively low PB pill burden., (© 2023 The Author(s). Published by S. Karger AG, Basel.)
- Published
- 2024
- Full Text
- View/download PDF
15. Managing Phosphate Burden in Patients Receiving Dialysis: Beyond Phosphate Binders and Diet.
- Author
-
Kalantar-Zadeh K, Forfang D, Bakris G, Martin KJ, Moe SM, and Sprague SM
- Subjects
- Humans, Renal Dialysis adverse effects, Quality of Life, Diet, Phosphates metabolism, Kidney Failure, Chronic therapy
- Abstract
Most patients receiving dialysis rely on dietary restriction and phosphate binders to minimize the risk of hyperphosphatemia, which is associated with increased mortality. However, dietary restriction is difficult because of hidden phosphate additives in processed foods and medications. Restriction of dietary phosphate sources such as protein may increase the risk of malnutrition. Phosphate binders, the only pharmacologic option for phosphate management since aluminum salts were introduced several decades ago, are often insufficient for binding the 1400-2500 mg of phosphate potentially consumed daily. Over the last decade, serum phosphate levels in the United States have risen, and >69% of patients receiving dialysis exhibited a most recent phosphate level >4.5 mg/dl (above the normal range), indicating an urgent need for new, more effective therapies to manage phosphate burden. Novel, nonbinder therapies such as transcellular and paracellular phosphate absorption inhibitors may be used for phosphate management, and future studies should examine whether they allow fewer dietary restrictions for patients receiving dialysis, potentially improving patient quality of life and nutritional status. It is imperative that we collaborate to move beyond the restrictive approaches available today and provide patients and clinicians with an array of strategies so that they may choose the most appropriate patient-centered therapy., (Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Society of Nephrology.)
- Published
- 2023
- Full Text
- View/download PDF
16. Response to Alkali Administration in Women and Men With and Without CKD.
- Author
-
Pao AC, Shahzad SR, Song S, Ganesan C, Conti S, Leppert J, Cheung AK, Ix JH, Isakova T, Wolf M, Raj DS, Sprague SM, Fried LF, Gassman J, Fong P, Koike S, and Raphael KL
- Published
- 2023
- Full Text
- View/download PDF
17. Quantitative Blood Oxygenation Level Dependent Magnetic Resonance Imaging for Estimating Intra-renal Oxygen Availability Demonstrates Kidneys Are Hypoxemic in Human CKD.
- Author
-
Prasad PV, Li LP, Hack B, Leloudas N, and Sprague SM
- Abstract
Introduction: Kidney blood oxygenation level dependent (BOLD) magnetic resonance imaging (MRI) has shown great promise in evaluating relative oxygen availability. This method is quite efficacious in evaluating acute responses to physiological and pharmacologic maneuvers. Its outcome parameter, R2∗ is defined as the apparent spin-spin relaxation rate measured in the presence of magnetic susceptibility differences and it is measured using gradient echo MRI. Although associations between R2∗ and renal function decline have been described, it remains uncertain to what extent R2∗ is a true reflection of tissue oxygenation. This is primarily because of not taking into account the confounding factors, especially fractional blood volume (fBV) in tissue., Methods: This case-control study included 7 healthy controls and 6 patients with diabetes and chronic kidney disease (CKD). Using data before and after administration of ferumoxytol, a blood pool MRI contrast media, the fBVs in kidney cortex and medulla were measured., Results: This pilot study independently measured fBV in kidney cortex (0.23 ± 0.03 vs. 0.17 ± 0.03) and medulla (0.36 ± 0.08 vs. 0.25 ± 0.03) in a small number of healthy controls ( n = 7) versus CKD ( n = 6). These were then combined with BOLD MRI measurements to estimate oxygen saturation of hemoglobin (StO
2 ) (0.87 ± 0.03 vs. 0.72 ± 0.10 in cortex; 0.82 ± 0.05 vs. 0.72 ± 0.06 in medulla) and partial pressure of oxygen in blood (bloodPO2 ) (55.4 ± 6.5 vs. 38.4 ± 7.6 mm Hg in cortex; 48.4 ± 6.2 vs. 38.1 ± 4.5 mm Hg in medulla) in control versus CKD. The results for the first time demonstrate that cortex is normoxemic in controls and moderately hypoxemic in CKD. In the medulla, it is mildly hypoxemic in controls and moderately hypoxemic in CKD. Whereas fBV, StO2 , and bloodPO2 were strongly associated with estimated glomerular filtration rate (eGFR), R2∗ was not., Conclusion: Our results support the feasibility of quantitatively assessing oxygen availability using noninvasive quantitative BOLD MRI that could be translated to the clinic., (© 2023 Published by Elsevier Inc. on behalf of the International Society of Nephrology.)- Published
- 2023
- Full Text
- View/download PDF
18. High Phosphate-Binding Capacity of Oxylanthanum Carbonate with a Low Medication Volume: Comparison with Commercially Available Phosphate Binders.
- Author
-
Sprague SM, Reddy G, Jermasek D, and Gupta P
- Subjects
- Humans, Quality of Life, Phosphates metabolism, Carbonates therapeutic use, Tablets therapeutic use, Chelating Agents therapeutic use, Lanthanum, Hyperphosphatemia drug therapy, Hyperphosphatemia etiology
- Abstract
Background: A key focus for chronic kidney disease management is phosphate control, but currently available binders have suboptimal phosphate-binding capacity, and their characteristics result in low adherence and poor phosphate regulation. Oxylanthanum carbonate, a novel compound that uses proprietary nanoparticle technology to deliver lanthanum, has the potential to combine high phosphate-binding capacity with good intake convenience, thus improving adherence and patient quality of life. The goal of this study was to assess the volume of oxylanthanum Carbonate required to bind 1 g of phosphate and compare it with other currently available phosphate binders to determine which binder allows for the highest normalized potency with the lowest daily medication volume., Methods: Six phosphate binders were assessed: ferric citrate, calcium acetate, lanthanum carbonate, sevelamer carbonate, sucroferric oxyhydroxide, and oxylanthanum carbonate. Table volume measurements were taken using fluid displacement in corn oil or water. Mean daily dose volume to bind 1 g of phosphate was calculated as volume per tablet multiplied by the mean number of tablets taken per day. Volume to bind 1 g of phosphate was calculated by dividing the volume per tablet by its in vivo binding capacity., Results: Oxylanthanum carbonate had the lowest mean volume, daily phosphate binder dose volume, and equivalent phosphate-binding dose volume (volume to bind 1 g of phosphate for each binder)., Conclusions: Oxylanthanum carbonate has the lowest daily phosphate binder dose volume and the smallest volume required to bind 1 g of phosphate compared to all other commercially available phosphate binders. A randomized trial that compares gastrointestinal tolerability across binders would be warranted to demonstrate acceptability and adherence in the target population., (© 2023 The Author(s). Published by S. Karger AG, Basel.)
- Published
- 2023
- Full Text
- View/download PDF
19. The American Association of Endocrine Surgeons Guidelines for the Definitive Surgical Management of Secondary and Tertiary Renal Hyperparathyroidism.
- Author
-
Dream S, Kuo LE, Kuo JH, Sprague SM, Nwariaku FE, Wolf M, Olson JA Jr, Moe SM, Lindeman B, and Chen H
- Subjects
- Humans, Kidney, Parathyroidectomy methods, United States epidemiology, Hyperparathyroidism, Secondary etiology, Hyperparathyroidism, Secondary surgery, Kidney Failure, Chronic complications, Kidney Failure, Chronic surgery, Surgeons
- Abstract
Objective: To develop evidence-based recommendations for safe, effective, and appropriate treatment of secondary (SHPT) and tertiary (THPT) renal hyperparathyroidism., Background: Hyperparathyroidism is common among patients with chronic kidney disease, end-stage kidney disease, and kidney transplant. The surgical management of SHPT and THPT is nuanced and requires a multidisciplinary approach. There are currently no clinical practice guidelines that address the surgical treatment of SHPT and THPT., Methods: Medical literature was reviewed from January 1, 1985 to present January 1, 2021 by a panel of 10 experts in SHPT and THPT. Recommendations using the best available evidence was constructed. The American College of Physicians grading system was used to determine levels of evidence. Recommendations were discussed to consensus. The American Association of Endocrine Surgeons membership reviewed and commented on preliminary drafts of the content., Results: These clinical guidelines present the epidemiology and pathophysiology of SHPT and THPT and provide recommendations for work-up and management of SHPT and THPT for all involved clinicians. It outlines the preoperative, intraoperative, and postoperative management of SHPT and THPT, as well as related definitions, operative techniques, morbidity, and outcomes. Specific topics include Pathogenesis and Epidemiology, Initial Evaluation, Imaging, Preoperative and Perioperative Care, Surgical Planning and Parathyroidectomy, Adjuncts and Approaches, Outcomes, and Reoperation., Conclusions: Evidence-based guidelines were created to assist clinicians in the optimal management of secondary and tertiary renal hyperparathyroidism., Competing Interests: S.M.M.: Scientific Advisor to Amgen, Ardelyx, and Sanifit. S.M.S.: Research Grants Amgen, Ardelyx, and Opko, Consulting Ardelyx. M.W. has received research support, honoraria or consultant fees from Akebia, Ardelyx, AstraZeneca, Bayer, Jnana, Pharmacosmos, Unicycive, and Walden Biosciences and has equity interests in Akebia, Unicycive and Walden Biosciences. The remaining authors report no conflicts of interest., (Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
20. Radiomics-Based Image Phenotyping of Kidney Apparent Diffusion Coefficient Maps: Preliminary Feasibility & Efficacy.
- Author
-
Li LP, Leidner AS, Wilt E, Mikheev A, Rusinek H, Sprague SM, Kohn OF, Srivastava A, and Prasad PV
- Abstract
Given the central role of interstitial fibrosis in disease progression in chronic kidney disease (CKD), a role for diffusion-weighted MRI has been pursued. We evaluated the feasibility and preliminary efficacy of using radiomic features to phenotype apparent diffusion coefficient (ADC) maps and hence to the clinical classification(s) of the participants. The study involved 40 individuals (10 healthy and 30 with CKD (eGFR < 60 mL/min/1.73 m2)). Machine learning methods, such as hierarchical clustering and logistic regression, were used. Clustering resulted in the identification of two clusters, one including all individuals with CKD (n = 17), while the second one included all the healthy volunteers (n = 10) and the remaining individuals with CKD (n = 13), resulting in 100% specificity. Logistic regression identified five radiomic features to classify participants as with CKD vs. healthy volunteers, with a sensitivity and specificity of 93% and 70%, respectively, and an AUC of 0.95. Similarly, four radiomic features were able to classify participants as rapid vs. non-rapid CKD progressors among the 30 individuals with CKD, with a sensitivity and specificity of 71% and 43%, respectively, and an AUC of 0.75. These promising preliminary data should support future studies with larger numbers of participants with varied disease severity and etiologies to improve performance.
- Published
- 2022
- Full Text
- View/download PDF
21. Sucroferric oxyhydroxide for hyperphosphatemia: a review of real-world evidence.
- Author
-
Coyne DW, Sprague SM, Vervloet M, Ramos R, and Kalantar-Zadeh K
- Subjects
- Drug Combinations, Ferric Compounds therapeutic use, Humans, Iron therapeutic use, Phosphates, Phosphorus, Prospective Studies, Randomized Controlled Trials as Topic, Renal Dialysis adverse effects, Retrospective Studies, Sucrose therapeutic use, Hyperphosphatemia drug therapy, Hyperphosphatemia etiology
- Abstract
Hyperphosphatemia is a common complication in dialysis-dependent patients with chronic kidney disease. Most dialysis-dependent patients need oral phosphate binder therapy to control serum phosphorus concentrations. Most phosphate binders have a high daily pill burden, which may reduce treatment adherence and impair phosphorus control. Sucroferric oxyhydroxide is a potent iron-based phosphate binder approved for use in dialysis-dependent patients in 2013. A randomized controlled trial of sucroferric oxyhydroxide demonstrated its efficacy for reduction of serum phosphorus with a lower pill burden than sevelamer carbonate. Clinical trials carefully select patients, monitor adherence, and routinely titrate medications to a protocol-defined goal. Consequently, trials may not reflect real-world use of medications. Since its approval, we and others have performed retrospective and prospective analyses of sucroferric oxyhydroxide in real-world clinical practice in > 6400 hemodialysis and approximately 500 peritoneal dialysis patients in the USA and Europe. Consistent with the clinical trial data, real-world observational studies have demonstrated that sucroferric oxyhydroxide can effectively reduce serum phosphorus with a lower daily pill burden than most other phosphate binders. These studies have also shown sucroferric oxyhydroxide provides effective serum phosphorus control in different treatment settings, including as monotherapy in phosphate binder-naïve patients, in patients switching from other phosphate binders, or when used in combination with other phosphate binders. These observational studies indicate a favorable safety and tolerability profile, and minimal, if any, systemic iron absorption. This article reviews the key results from these observational studies of sucroferric oxyhydroxide and evaluates its role in the management of hyperphosphatemia in clinical practice., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
22. A safety evaluation of sucroferric oxyhydroxide for the treatment of hyperphosphatemia.
- Author
-
Sprague SM and Ketteler M
- Subjects
- Chelating Agents administration & dosage, Drug Combinations, Drug Interactions, Ferric Compounds administration & dosage, Humans, Hyperphosphatemia etiology, Renal Dialysis, Renal Insufficiency, Chronic complications, Renal Insufficiency, Chronic therapy, Sucrose administration & dosage, Chelating Agents adverse effects, Ferric Compounds adverse effects, Hyperphosphatemia drug therapy, Sucrose adverse effects
- Abstract
Introduction: Hyperphosphatemia is a common complication as chronic kidney disease (CKD) progresses and most patients undergoing dialysis are prescribed oral phosphate binder therapy to control serum phosphate concentrations. Sucroferric oxyhydroxide is an iron-based phosphate binder approved for the treatment of hyperphosphatemia in CKD patients on dialysis., Areas Covered: This article reviews key safety and effectiveness data for sucroferric oxyhydroxide from both prospective clinical trials and real-world observational studies., Expert Opinion: Sucroferric oxyhydroxide potently binds dietary phosphate in the gastrointestinal (GI) tract, resulting in effective reduction of serum phosphate concentrations with a relatively low daily pill burden. Data from clinical trials and real-world observational studies show sucroferric oxyhydroxide has a favorable safety and tolerability profile. The most frequent side effects observed with sucroferric oxyhydroxide are GI-related, mainly discolored (black) stools and mild or moderate transient diarrhea, both of which are manageable. There is minimal systemic iron absorption from sucroferric oxyhydroxide, and therefore the drug is associated with a low risk of iron accumulation. Sucroferric oxyhydroxide also displays low potential for drug-drug interactions with other commonly prescribed oral medications. Overall, sucroferric oxyhydroxide offers an effective and well-tolerated treatment option for the management of hyperphosphatemia.
- Published
- 2021
- Full Text
- View/download PDF
23. Abnormalities in Cardiac Structure and Function among Individuals with CKD: The COMBINE Trial.
- Author
-
Wang AA, Cai X, Srivastava A, Prasad PV, Sprague SM, Carr J, Wolf M, Ix JH, Block GA, Chonchol M, Raphael KL, Cheung AK, Raj DS, Gassman JJ, Rahsepar AA, Middleton JP, Fried LF, Sarnari R, Isakova T, and Mehta R
- Subjects
- Albuminuria complications, Creatinine urine, Cross-Sectional Studies, Glomerular Filtration Rate, Humans, Renal Insufficiency, Chronic complications
- Abstract
Background: Individuals with CKD have a high burden of cardiovascular disease (CVD). Abnormalities in cardiac structure and function represent subclinical CVD and can be assessed by cardiac magnetic resonance imaging (cMRI)., Methods: We investigated differences in cMRI parameters in 140 individuals with CKD stages 3b-4 who participated in the CKD Optimal Management with BInders and NicotinamidE (COMBINE) trial and in 24 age- and sex-matched healthy volunteers. Among COMBINE participants, we examined the associations of eGFR, urine albumin-creatinine ratio (UACR), phosphate, fibroblast growth factor 23 (FGF23), and parathyroid hormone (PTH) with baseline ( N =140) and 12-month change ( N =112) in cMRI parameters., Results: Mean (SD) ages of the COMBINE participants and healthy volunteers were 64.9 (11.9) and 60.4 (7.3) years, respectively. The mean (SD) baseline eGFR values in COMBINE participants were 32.1 (8.0) and 85.9 (16.0) ml/min per 1.73 m
2 in healthy volunteers. The median (interquartile range [IQR]) UACR in COMBINE participants was 154 (20.3-540.0) mg/g. Individuals with CKD had lower mitral valve E/A ratio compared with healthy volunteers (for CKD versus non-CKD, β estimate, -0.13; 95% CI, -0.24 to -0.012). Among COMBINE participants, multivariable linear regression analyses showed that higher UACR was significantly associated with lower mitral valve E/A ratio ( β estimate per 1 unit increase in natural-log UACR, -0.06; 95% CI, -0.09 to -0.03). This finding was preserved among individuals without baseline CVD. UACR was not associated with 12-month change in any cMRI parameter. eGFR, phosphate, FGF23, and PTH were not associated with any cMRI parameter in cross-sectional or change analyses., Conclusions: Individuals with CKD stages 3b-4 have evidence of cMRI abnormalities. Albuminuria was independently associated with diastolic dysfunction, as assessed by mitral valve E/A ratio, in individuals with CKD with and without clinical CVD. Albuminuria was not associated with change in any cMRI parameter., Competing Interests: G.A. Block reports receiving research funding from Akebia, Ardelyx, and GlaxoSmithKline; having consultancy agreements with Akebia, Keryx, Kirin, and Reata; receiving honoraria from Amgen and Kirin; serving as a scientific advisor for or member of Ardelyx, CJASN, Kirin, and Reata; having ownership interest in Ardelyx and Reata; and having other interests in/relationships with DaVita (previously medical director), Kidney Disease Improving Global Outcomes (previously on Executive Commitee), and Reata (previous employment). J. Carr reports serving on a speakers bureau for Bayer; receiving honoraria from Bayer, Bracco, and Guerbet; having consultancy agreements with Bayer, Bracco, and Siemens; receiving research funding from Bayer, Guerbet, and Siemens; and serving as a scientific advisor for or member of the Society for Cardiovascular MRI. A.K. Cheung reports having consultancy agreements with, and receiving honoraria from, Boehringer Ingelheim, Calliditas, and UptoDate; serving as a scientific advisor for or member of Hong Kong Journal of Nephrology, JASN, and Kidney Diseases; having other interests in/relationships with KDIGO; and having ownership interest in Merck. M. Chonchol reports having consultancy agreements with Amgen, Corvidia, Otsuka, Reata, Tricidia, and Vifor; receiving honoraria from Amgen, Corvidia, Reata, Tricidia, and Vifor; serving as a scientific advisor for or member of the CJASN editorial board; and receiving research funding from the Corvidia, National Institutes of Health (NIH), Otsuka, Reata, and Sanofi. L.F. Fried reports having consultancy agreements with Bayer, and serving on data safety monitoring boards for CSL Behring and Novo Nordisk. J.J. Gassman reports having consultancy agreements with, and receiving honoraria from, the Baim Institute (Harvard Clinical Research Institute). T. Isakova reports having consultancy agreements with, and receiving honoraria from, Akebia Therapeutics Inc.; and serving as an associate editor of American Journal of Kidney Diseases. J.H. Ix reports serving as a scientific advisor for or member of AlphaYoung; having consultancy agreements with Ardelyx, AstraZeneca, Bayer, Jnana, and Sanifit; and receiving research funding from Baxter International. R. Mehta reports having ownership interest in AbbVie Inc.; having consultancy agreements with, and receiving honoraria from, Akebia/Otsuka and AstraZeneca; and serving on the editorial board of the Journal of Cardiac Failure. J.P. Middleton reports serving on the editorial board for Advances in Chronic Kidney Disease and on a data safety monitoring board for the NIDDK; having consultancy agreements with AstraZeneca and Vifor/Relypsa; receiving research funding from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and Vifor/Relypsa; having other interests in/relationships with Raleigh Radiology (via spouse); and receiving honoraria from Relypsa/Vifor. D.S. Raj reports having other interests in/relationships with the American Association of Kidney Patients; serving as a scientific advisor for or member of the National Heart, Lung, and Blood Institute (NHLBI), NIDDK, and Novo Nordisk; receiving research funding from NIH; and having consultancy agreements with, and receiving honoraria from, Novo Nordisk. K.L. Raphael reports having consultancy agreements with AstraZeneca. S.M. Sprague reports serving as a scientific advisor for or member of the American Association of Endocrine Surgeons American Journal of Nephrology, International Federation of Clinical Chemistry and Laboratory Medicine Work Group for Parathyroid Hormone, and National Kidney Foundation of Illinois; having consultancy agreements with Amgen, Ardelyx, Fresenius, Horizon, Litholink Corp., OPKO, Shire, and Vifor; receiving research funding from Amgen, Ardelyx, OPKO, and Reata; receiving honoraria from Amgen, Ardelyx, Fresenius, Horizon, OPKO, and Vifor; serving on speakers bureaus for Amgen, Fresenius, Horizon, and OPKO; and having ownership interest via individually owned stocks in Apple, Bristol Myers, Coca Cola, First Australia Fund, IBM, Paycheck, US Concrete, and Walgreens. A. Srivastava reports serving on a speaker’s bureau for AstraZeneca; receiving honoraria from AstraZeneca, Bayer, and Horizon Therapeutics PLC; and having consultancy agreements with CVS Caremark and Tate & Latham (medicolegal consulting). M. Wolf reports having consultancy agreements with, and receiving honoraria from, Akebia, Amgen, Ardelyx, AstraZeneca, Bayer, Pharmacosmos, Unicycive, and Walden; and having ownership interest in, and serving as a scientific advisor for or member of, Akebia, Unicycive, and Walden. All remaining authors have nothing to disclose.All remaining authors have nothing to disclose., (Copyright © 2022 by the American Society of Nephrology.)- Published
- 2021
- Full Text
- View/download PDF
24. Neuroprotective Roles of the Adenosine A 3 Receptor Agonist AST-004 in Mouse Model of Traumatic Brain Injury.
- Author
-
Bozdemir E, Vigil FA, Chun SH, Espinoza L, Bugay V, Khoury SM, Holstein DM, Stoja A, Lozano D, Tunca C, Sprague SM, Cavazos JE, Brenner R, Liston TE, Shapiro MS, and Lechleiter JD
- Subjects
- Adenosine metabolism, Adenosine pharmacology, Animals, Astrocytes metabolism, Disease Models, Animal, Female, Gliosis metabolism, Male, Mice, Mice, Inbred C57BL, Neuroprotection, Brain Injuries, Traumatic complications, Brain Injuries, Traumatic drug therapy, Brain Injuries, Traumatic metabolism, Neuroprotective Agents metabolism, Neuroprotective Agents pharmacology, Neuroprotective Agents therapeutic use
- Abstract
Traumatic brain injury (TBI) remains one of the greatest public health concerns with increasing morbidity and mortality rates worldwide. Our group reported that stimulation of astrocyte mitochondrial metabolism by P2Y
1 receptor agonists significantly reduced cerebral edema and reactive gliosis in a TBI model. Subsequent data on the pharmacokinetics (PK) and rapid metabolism of these compounds suggested that neuroprotection was likely mediated by a metabolite, AST-004, which binding data indicated was an adenosine A3 receptor (A3 R) agonist. The neuroprotective efficacy of AST-004 was tested in a control closed cortical injury (CCCI) model of TBI in mice. Twenty-four (24) hours post-injury, mice subjected to CCCI and treated with AST-004 (0.22 mg/kg, injected 30 min post-trauma) exhibited significantly less secondary brain injury. These effects were quantified with less cell death (PSVue794 fluorescence) and loss of blood brain barrier breakdown (Evans blue extravasation assay), compared to vehicle-treated TBI mice. TBI-treated mice also exhibited significantly reduced neuroinflammatory markers, glial-fibrillary acidic protein (GFAP, astrogliosis) and ionized Ca2+ -binding adaptor molecule 1 (Iba1, microgliosis), both at the mRNA (qRT-PCR) and protein (Western blot and immunofluorescence) levels, respectively. Four (4) weeks post-injury, both male and female TBI mice presented a significant reduction in freezing behavior during contextual fear conditioning (after foot shock). AST-004 treatment prevented this TBI-induced impairment in male mice, but did not significantly affect impairment in female mice. Impairment of spatial memory, assessed 24 and 48 h after the initial fear conditioning, was also reduced in AST-004-treated TBI-male mice. Female TBI mice did not exhibit memory impairment 24 and 48 h after contextual fear conditioning and similarly, AST-004-treated female TBI mice were comparable to sham mice. Finally, AST-004 treatments were found to increase in vivo ATP production in astrocytes (GFAP-targeted luciferase activity), consistent with the proposed mechanism of action. These data reveal AST-004 as a novel A3 R agonist that increases astrocyte energy production and enhances their neuroprotective efficacy after brain injury., (© 2021. The American Society for Experimental NeuroTherapeutics, Inc.)- Published
- 2021
- Full Text
- View/download PDF
25. Family Genetic Screening to Identify Cases of Alport Syndrome: A Case Study Report.
- Author
-
Sprague SM and Warady BA
- Published
- 2021
- Full Text
- View/download PDF
26. Phosphate Balance and CKD-Mineral Bone Disease.
- Author
-
Sprague SM, Martin KJ, and Coyne DW
- Abstract
Chronic kidney disease-mineral bone disorder (CKD-MBD) is a common comorbidity in patients with CKD. Characterized by laboratory abnormalities, bone abnormality, and vascular calcification, CKD-MBD encompasses a group of mineral and hormone disturbances that are strongly associated with increased cardiovascular (CV) morbidity and mortality. Abnormal serum phosphate concentrations are an independent risk factor for CV morbidity and mortality, and overall mortality. Phosphate retention plays a central role in initiating and driving many other disturbances in CKD-MBD (e.g., increased parathyroid hormone and fibroblast growth factor 23 concentrations, hypocalcemia, low vitamin D) that are also linked to increased CV risk. Thus, effective phosphate control is a logical therapeutic target for CKD-MBD treatment. Current phosphate management strategies (dietary restrictions, dialysis, phosphate binders) are insufficient to consistently achieve and maintain target phosphate concentrations in patients on dialysis. Phosphate binders reduce available phosphate for intestinal absorption but do not impair the dominant phosphate absorption pathway. Novel therapies that consider new mechanistic understandings of intestinal phosphate absorption are needed. One such therapy is tenapanor, a targeted sodium-hydrogen exchanger isoform 3 inhibitor that has been shown to reduce serum phosphate concentrations in multiple clinical trials. Tenapanor has a novel mechanism of action that reduces intestinal phosphate absorption in the primary paracellular phosphate absorption pathway., (© 2021 International Society of Nephrology. Published by Elsevier Inc.)
- Published
- 2021
- Full Text
- View/download PDF
27. Small Intestinal Phosphate Absorption: Novel Therapeutic Implications.
- Author
-
Yee J, Rosenbaum D, Jacobs JW, and Sprague SM
- Subjects
- Animals, Biological Transport, Humans, Hyperphosphatemia etiology, Hyperphosphatemia physiopathology, Renal Insufficiency, Chronic complications, Sodium-Hydrogen Exchanger 3 antagonists & inhibitors, Hyperphosphatemia drug therapy, Intestinal Absorption, Intestine, Small physiopathology, Isoquinolines therapeutic use, Phosphates metabolism, Renal Insufficiency, Chronic physiopathology, Sulfonamides therapeutic use
- Abstract
Background: Chronic kidney disease (CKD) affects approximately 15% of adults in the USA. As CKD progresses, urinary phosphate excretion decreases and results in phosphate retention and, eventually, hyperphosphatemia. As hyperphosphatemia is associated with numerous adverse outcomes, including increased cardiovascular mortality, reduction in phosphorus concentrations is a guideline-recommended, established clinical practice. Dietary phosphate restriction, dialysis, and phosphate binders are currently the only options for phosphate management. However, many patients with hyperphosphatemia have phosphorus concentrations >5.5 mg/dL, despite treatment., Summary: This review pre-sents recent advances in the understanding of intestinal phosphate absorption and therapeutic implications. Dietary phosphate is absorbed in the intestine through two distinct pathways, paracellular absorption and transcellular transport. Recent evidence indicates that the paracellular route accounts for 65-80% of total phosphate absorbed. Thus, the paracellular pathway is the dominant mechanism of phosphate absorption. Tenapanor is a first-in-class, non-phosphate binder that inhibits the sodium-hydrogen exchanger 3 or solute carrier family 9 member 3 (SLC9A3) encoded by the SLC9A3 gene, and blocks paracellular phosphate absorption. Key Messages: Targeted inhibition of sodium-hydrogen exchanger 3 effectively reduces paracellular permeability of phosphate. Novel therapies that target the paracellular pathway may improve phosphate control in chronic kidney disease., (© 2021 The Author(s). Published by S. Karger AG, Basel.)
- Published
- 2021
- Full Text
- View/download PDF
28. The Enigma of Vascular Calcifications.
- Author
-
Sprague SM
- Published
- 2020
- Full Text
- View/download PDF
29. Secondary Hyperparathyroidism in a Patient with CKD.
- Author
-
Hyder R and Sprague SM
- Subjects
- Calcimimetic Agents therapeutic use, Calcitriol therapeutic use, Chelating Agents therapeutic use, Cholecalciferol therapeutic use, Ergocalciferols therapeutic use, Humans, Hyperparathyroidism, Secondary etiology, Male, Middle Aged, Parathyroid Hormone blood, Parathyroidectomy, Phosphates blood, Phosphorus, Dietary, Polycystic Kidney, Autosomal Dominant complications, Renal Insufficiency, Chronic complications, Vitamin D analogs & derivatives, Vitamin D blood, Vitamin D Deficiency etiology, Hyperparathyroidism, Secondary physiopathology, Hyperparathyroidism, Secondary therapy, Renal Insufficiency, Chronic physiopathology, Vitamin D Deficiency drug therapy
- Published
- 2020
- Full Text
- View/download PDF
30. Kidney Functional Magnetic Resonance Imaging and Change in eGFR in Individuals with CKD.
- Author
-
Srivastava A, Cai X, Lee J, Li W, Larive B, Kendrick C, Gassman JJ, Middleton JP, Carr J, Raphael KL, Cheung AK, Raj DS, Chonchol MB, Fried LF, Block GA, Sprague SM, Wolf M, Ix JH, Prasad PV, and Isakova T
- Subjects
- Aged, Drug Therapy, Combination, Female, Fibrosis, Glomerular Filtration Rate, Humans, Kidney pathology, Kidney physiopathology, Lanthanum therapeutic use, Male, Middle Aged, Niacinamide therapeutic use, Renal Insufficiency, Chronic drug therapy, Vitamin B Complex therapeutic use, Diffusion Magnetic Resonance Imaging, Kidney diagnostic imaging, Renal Insufficiency, Chronic diagnostic imaging, Renal Insufficiency, Chronic physiopathology
- Abstract
Background and Objectives: Kidney functional magnetic resonance imaging (MRI) requires further investigation to enhance the noninvasive identification of patients at high risk of CKD progression., Design, Setting, Participants, & Measurements: In this exploratory study, we obtained baseline diffusion-weighted and blood oxygen level-dependent MRI in 122 participants of the CKD Optimal Management with Binders and Nicotinamide trial, which was a multicenter, randomized, double-blinded, 12-month, four-group parallel trial of nicotinamide and lanthanum carbonate versus placebo conducted in individuals with eGFR 20-45 ml/min per 1.73 m
2 . Lower values of apparent diffusion coefficient (ADC) on diffusion-weighted MRI may indicate increased fibrosis, and higher values of relaxation rate (R2*) on blood oxygen level-dependent MRI may represent decreased oxygenation. Because there was no effect of active treatment on eGFR over 12 months, we tested whether baseline kidney functional MRI biomarkers were associated with eGFR decline in all 122 participants. In a subset of 87 participants with 12-month follow-up MRI data, we evaluated whether kidney functional MRI biomarkers change over time., Results: Mean baseline eGFR was 32±9 ml/min per 1.73 m2 , and mean annual eGFR slope was -2.3 (95% confidence interval [95% CI], -3.4 to -1.1) ml/min per 1.73 m2 per year. After adjustment for baseline covariates, baseline ADC was associated with change in eGFR over time (difference in annual eGFR slope per 1 SD increase in ADC: 1.3 [95% CI, 0.1 to 2.5] ml/min per 1.73 m2 per year, ADC×time interaction P =0.04). This association was no longer significant after further adjustment for albuminuria (difference in annual eGFR slope per 1 SD increase in ADC: 1.0 (95% CI, -0.1 to 2.2) ml/min per 1.73 m2 per year, ADC×time interaction P =0.08). There was no significant association between baseline R2* and change in eGFR over time. In 87 participants with follow-up functional MRI, ADC and R2* values remained stable over 12 months (intraclass correlation: 0.71 and 0.68, respectively)., Conclusions: Baseline cortical ADC was associated with change in eGFR over time, but this association was not independent of albuminuria. Kidney functional MRI biomarkers remained stable over 1 year., Clinical Trial Registry Name and Registration Number: CKD Optimal Management with Binders and Nicotinamide (COMBINE), NCT02258074., (Copyright © 2020 by the American Society of Nephrology.)- Published
- 2020
- Full Text
- View/download PDF
31. Prevention of brain damage after traumatic brain injury by pharmacological enhancement of KCNQ (Kv7, "M-type") K + currents in neurons.
- Author
-
Vigil FA, Bozdemir E, Bugay V, Chun SH, Hobbs M, Sanchez I, Hastings SD, Veraza RJ, Holstein DM, Sprague SM, M Carver C, Cavazos JE, Brenner R, Lechleiter JD, and Shapiro MS
- Subjects
- Animals, Mice, Mice, Inbred C57BL, Anticonvulsants pharmacology, Brain Injuries, Traumatic metabolism, Carbamates pharmacology, KCNQ Potassium Channels metabolism, Neurons drug effects, Neurons metabolism, Phenylenediamines pharmacology
- Abstract
Nearly three million people in the USA suffer traumatic brain injury (TBI) yearly; however, there are no pre- or post-TBI treatment options available. KCNQ2-5 voltage-gated K
+ channels underlie the neuronal "M current", which plays a dominant role in the regulation of neuronal excitability. Our strategy towards prevention of TBI-induced brain damage is predicated on the suggested hyper-excitability of neurons induced by TBIs, and the decrease in neuronal excitation upon pharmacological augmentation of M/KCNQ K+ currents. Seizures are very common after a TBI, making further seizures and development of epilepsy disease more likely. Our hypothesis is that TBI-induced hyperexcitability and ischemia/hypoxia lead to metabolic stress, cell death and a maladaptive inflammatory response that causes further downstream morbidity. Using the mouse controlled closed-cortical impact blunt TBI model, we found that systemic administration of the prototype M-channel "opener", retigabine (RTG), 30 min after TBI, reduces the post-TBI cascade of events, including spontaneous seizures, enhanced susceptibility to chemo-convulsants, metabolic stress, inflammatory responses, blood-brain barrier breakdown, and cell death. This work suggests that acutely reducing neuronal excitability and energy demand via M-current enhancement may be a novel model of therapeutic intervention against post-TBI brain damage and dysfunction.- Published
- 2020
- Full Text
- View/download PDF
32. Iron kinetics following treatment with sucroferric oxyhydroxide or ferric citrate in healthy rats and models of anaemia, iron overload or inflammation.
- Author
-
Floege J, Funk F, Ketteler M, Rastogi A, Walpen S, Covic AC, and Sprague SM
- Subjects
- Administration, Oral, Anemia pathology, Animals, Drug Combinations, Female, Inflammation pathology, Iron Overload pathology, Kinetics, Male, Rats, Rats, Sprague-Dawley, Rats, Wistar, Tissue Distribution, Anemia drug therapy, Ferric Compounds administration & dosage, Inflammation drug therapy, Iron pharmacokinetics, Iron Overload drug therapy, Sucrose administration & dosage
- Abstract
Background: The iron-based phosphate binders, sucroferric oxyhydroxide (SFOH) and ferric citrate (FC), effectively lower serum phosphorus in clinical studies, but gastrointestinal iron absorption from these agents appears to differ. We compared iron uptake and tissue accumulation during treatment with SFOH or FC using experimental rat models., Methods: Iron uptake was evaluated during an 8-h period following oral administration of SFOH, FC, ferrous sulphate (oral iron supplement) or control (methylcellulose vehicle) in rat models of anaemia, iron overload and inflammation. A 13-week study evaluated the effects of SFOH and FC on iron accumulation in different organs., Results: In the pharmacokinetic experiments, there was a minimal increase in serum iron with SFOH versus control during the 8-h post-treatment period in the iron overload and inflammation rat models, whereas a moderate increase was observed in the anaemia model. Significantly greater increases (P < 0.05) in serum iron were observed with FC versus SFOH in the rat models of anaemia and inflammation. In the 13-week iron accumulation study, total liver iron content was significantly higher in rats receiving FC versus SFOH (P < 0.01), whereas liver iron content did not differ between rats in the SFOH and control groups., Conclusions: Iron uptake was higher from FC versus SFOH following a single dose in anaemia, iron overload and inflammation rat models and 13 weeks of treatment in normal rats. These observations likely relate to different physicochemical properties of SFOH and FC and suggest distinct mechanisms of iron absorption from these two phosphate binders., (© The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA.)
- Published
- 2020
- Full Text
- View/download PDF
33. Interventions for Preventing Bone Disease Following Kidney Transplantation: Is There Evidence for Specific Therapy?
- Author
-
Sprague SM
- Subjects
- Humans, Immunosuppressive Agents, Bone Diseases, Kidney Transplantation
- Published
- 2020
- Full Text
- View/download PDF
34. Sucroferric Oxyhydroxide in Maintenance Hemodialysis: A Retrospective, Comparative Cohort Study.
- Author
-
Coyne DW, Ficociello LH, Parameswaran V, Rosen MM, Mullon C, Kossmann RJ, and Sprague SM
- Abstract
Rationale & Objective: High pill burden associates with reduced phosphate-binder adherence among dialysis patients, contributing to elevated serum phosphorus levels. We compared the real-world effectiveness of sucroferric oxyhydroxide (SO) versus other phosphate binders in hemodialysis patients over 2 years., Study Design: Retrospective cohort study., Setting & Participants: Adult in-center hemodialysis patients prescribed 2 years of uninterrupted SO therapy (maintenance SO; n = 222) compared with patients who discontinued SO therapy (discontinued SO; n = 596) within 90 days of first prescription and switched to other phosphate binder(s) for 2 years., Exposures: Phosphate binders., Outcomes: Achievement of serum phosphorus levels ≤ 5.5 mg/dL, pill burden, and hospitalizations., Analytical Approach: Comparisons were made quarterly (Q1-Q8) between maintenance SO and discontinued SO using Poisson and mixed-effects linear regression., Results: Patients achieving serum phosphorus levels ≤ 5.5 mg/dL increased from baseline in maintenance SO (46 [20.7%] to a maximum of 104 [46.8%; P < 0.001]) and discontinued SO (96 [16.1%] to a maximum of 201 [33.7%]; P < 0.001). 100 (45%) maintenance SO patients achieved target serum phosphorus levels at Q8 with 3.1 fewer pills per day from baseline (7.5 to 4.4 pills per day; P < 0.001), and 190 (31.9%) discontinued SO patients achieved serum phosphorus levels ≤ 5.5 mg/dL at Q8 with pill burden unchanged (9.1 to 9.3 pills per day; P = 0.3). Among all patients during 2 years, mean serum phosphorus levels decreased by -0.66 mg/dL and -0.45 mg/dL (maintenance SO vs discontinued SO; P = 0.014), and mean pill burden decreased in maintenance SO (8.5 to 5.1 pills per day; P < 0.001), but not in discontinued SO (11.6 to 10.9 pills per day; P = 0.2). The serum phosphorus level decrease with SO was confirmed in a sensitivity analysis including patients with SO therapy for 2 or fewer years. Compared with discontinued SO, maintenance SO patients had 35.6 fewer hospitalizations per 100 patient-years (incidence rate ratio, 0.75 [95% CI, 0.58-0.96])., Limitations: No data for treatment indication, tolerance, or adherence., Conclusions: Patients maintained on SO therapy were more likely to achieve target serum phosphorus levels, use 50% fewer phosphate-binder pills per day, and have fewer hospital admissions than patients switched to treatment with other binders., (© 2020 The Authors.)
- Published
- 2020
- Full Text
- View/download PDF
35. Medullary Blood Oxygen Level-Dependent MRI Index (R2*) is Associated with Annual Loss of Kidney Function in Moderate CKD.
- Author
-
Li LP, Thacker JM, Li W, Hack B, Wang C, Kohn O, Sprague SM, and Prasad PV
- Subjects
- Aged, Disease Progression, Female, Glomerular Filtration Rate, Humans, Male, Middle Aged, Renal Insufficiency, Chronic physiopathology, Severity of Illness Index, Time Factors, Kidney Medulla blood supply, Magnetic Resonance Imaging, Oxygen blood, Renal Insufficiency, Chronic blood, Renal Insufficiency, Chronic diagnostic imaging
- Abstract
Background: The estimated glomerular filtration rate (eGFR) is frequently used to monitor progression of kidney disease. Multiple values have to be obtained, sometimes over years to determine the rate of decline in kidney function. Recent data suggest that functional MRI (fMRI) methods may be able to predict loss of eGFR. In a prior study, baseline data with multi-parametric MRI in individuals with diabetes and moderate CKD was reported. This report extends our prior observations in order to evaluate the temporal variability of the fMRI measurements over 36 months and their association with annual change in eGFR., Methods: Twenty-four subjects with moderate CKD completed 3 sets of MRI scans over a 36-month period. Blood oxygenation level-dependent (BOLD), arterial spin labeling perfusion, and diffusion MRI images were acquired using a 3 T scanner. Coefficients of variation was used to evaluate variability between subjects at each time point and temporal variability within each subject. We have conducted mixed effects models to examine the trajectory change in GFR over time using time and MRI variables as fixed effects and baseline intercept as random effect. Associations of MRI image markers with annual change in eGFR were evaluated., Results: Multi-parametric functional renal MRI techniques in individuals with moderate CKD showed higher temporal variability in R2* of medulla compared to healthy individuals. This was consistent with the significant lower R2* in medulla observed at 36 months compared to baseline values. The results of linear mixed model showing that R2*_Medulla was the only predictor associated with change in eGFR over time. Furthermore, a significant association of medullary R2* with annual loss of eGFR was observed at all the 3 time points., Conclusions: The lower R2* values and the higher temporal variability in the renal medulla over time suggest the ability to monitor progressive CKD. These were confirmed by the fact that reduced medullary R2* was associated with higher annual loss in eGFR. These data collectively emphasize the need for inclusion of medulla in the analysis of renal BOLD MRI studies., (© 2021 S. Karger AG, Basel.)
- Published
- 2020
- Full Text
- View/download PDF
36. A Randomized Trial Comparing the Safety, Adherence, and Pharmacodynamics Profiles of Two Doses of Sodium Bicarbonate in CKD: the BASE Pilot Trial.
- Author
-
Raphael KL, Isakova T, Ix JH, Raj DS, Wolf M, Fried LF, Gassman JJ, Kendrick C, Larive B, Flessner MF, Mendley SR, Hostetter TH, Block GA, Li P, Middleton JP, Sprague SM, Wesson DE, and Cheung AK
- Subjects
- Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Pilot Projects, Sodium Bicarbonate adverse effects, Medication Adherence statistics & numerical data, Renal Insufficiency, Chronic drug therapy, Sodium Bicarbonate administration & dosage, Sodium Bicarbonate pharmacokinetics
- Abstract
Background: Oral sodium bicarbonate (NaHCO
3 ) may preserve kidney function in CKD, even if initiated when serum bicarbonate concentration is normal. Adequately powered trials testing this hypothesis have not been conducted, partly because the best dose for testing is unknown., Methods: This multicenter pilot trial assessed the safety, tolerability, adherence, and pharmacodynamics of two doses of NaHCO3 over 28 weeks in adults with eGFR 20-44 or 45-59 ml/min per 1.73 m2 with urinary albumin/creatinine (ACR) ≥50 mg/g and serum bicarbonate 20-28 meq/L. We randomly assigned 194 participants from ten clinical sites to receive higher-dose (HD-NaHCO3 ; 0.8 meq/kg of lean body wt per day; n =90) or lower-dose (LD-NaHCO3 ; 0.5 meq/kg of lean body wt per day; n =52) NaHCO3 or matching placebo ( n =52). The dose was adjusted depending on side effects. The prescribed dose at week 28 was the primary outcome; a dose was considered acceptable for a full-scale trial if ≥67% of participants were on full-dose and ≥80% were on ≥25% of the per-protocol dose., Results: Mean±SD baseline eGFR was 36±9 ml/min per 1.73 m2 , serum bicarbonate was 24±2 meq/L, and median (IQR) ACR was 181 (25-745) mg/g. Both doses were well tolerated without significant changes in BP, weight, or serum potassium. The proportions of adverse events and hospitalizations were similar across the groups. Consequently, 87% in HD-NaHCO3 , 96% in LD-NaHCO3 , and 87% in placebo were on full dose at week 28; and 91% in HD-NaHCO3 , 98% in LD-NaHCO3 , and 92% in placebo were on ≥25% of the per-protocol dose. Mean urinary ammonium excretion was 25% lower and serum bicarbonate concentration was 1.3 meq/L higher in HD-NaHCO3 compared with LD-NaHCO3 at week 28. However, mean ACR increased by 12% in the lower-dose group and 30% in the higher-dose group., Conclusions: Both NaHCO3 doses were well tolerated over 28 weeks with no significant difference in adverse events or hospitalization compared with placebo. The higher dose lowered urinary ammonium excretion and increased serum bicarbonate more than the lower dose but was associated with a greater increase in ACR. The higher 0.8 meq/kg of lean body wt per day dose of NaHCO3 may be a reasonable choice for future trials., (Copyright © 2020 by the American Society of Nephrology.)- Published
- 2020
- Full Text
- View/download PDF
37. Characteristics of Patients Who Achieve Serum Phosphorus Control on Sucroferric Oxyhydroxide or Sevelamer Carbonate: A post hoc Analysis of a Phase 3 Study.
- Author
-
Covic AC, Sprague SM, Rastogi A, Ketteler M, Walpen S, Perrin A, and Floege J
- Subjects
- Adult, Age Factors, Aged, Calcimimetic Agents administration & dosage, Chelating Agents administration & dosage, Chelating Agents adverse effects, Chelating Agents therapeutic use, Drug Combinations, Female, Ferric Compounds administration & dosage, Ferric Compounds adverse effects, Fibroblast Growth Factor-23, Fibroblast Growth Factors blood, Humans, Logistic Models, Male, Middle Aged, Parathyroid Hormone blood, Renal Dialysis adverse effects, Renal Dialysis methods, Renal Insufficiency, Chronic blood, Renal Insufficiency, Chronic complications, Renal Insufficiency, Chronic therapy, Sevelamer administration & dosage, Sevelamer adverse effects, Sucrose administration & dosage, Sucrose adverse effects, Vitamin D administration & dosage, Ferric Compounds therapeutic use, Hyperphosphatemia blood, Hyperphosphatemia drug therapy, Phosphorus blood, Sevelamer therapeutic use, Sucrose therapeutic use
- Abstract
Introduction: Control of hyperphosphatemia in patients on dialysis remains a major challenge., Objective: This study evaluated predictors of serum phosphorus (sP) control among dialysis patients treated with noncalcium, oral phosphate binder therapy in a phase 3 clinical trial., Methods: Post hoc analyses were performed using data for patients with hyperphosphatemia who received 52 weeks of treatment with sucroferric oxyhydroxide (SFOH) or sevelamer carbonate (sevelamer). Patients were categorized into those who achieved sP control (n = 302; defined as sP ≤ 5.5 mg/dL at week 52), and those with uncontrolled sP (n = 195; sP >5.5 mg/dL at week 52). Because SFOH and sevelamer have previously demonstrated similar effects on chronic kidney disease-mineral-bone disorder parameters in this study, the treatment groups were pooled., Results: Average age at baseline was higher among sP-controlled versus sP-uncontrolled patients (56.9 vs. 53.4 years; p = 0.005). Baseline sP levels were significantly lower among sP-controlled versus sP-uncontrolled patients (7.30 vs. 7.85 mg/dL; p < 0.001), and sP reductions from baseline were significantly greater in the sP-controlled group (-2.89 vs. -0.99 mg/dL at week 52; p < 0.001). Logistic regression analysis identified higher baseline sP levels (odds ratio [OR] = 0.86, 95% confidence interval [CI]: 0.765-0.960), no concomitant active vitamin D therapy use (OR = 0.51, 95% CI: 0.328-0.804), and higher body mass index at baseline (OR = 0.96, 95% CI: 0.937-0.992) as significant predictors of uncontrolled sP., Conclusion: This analysis indicates that sP control may be more challenging in younger patients with high sP levels. Closer monitoring and management of serum phosphorus levels may be required in this population., (The Author(s). Published by S. Karger AG, Basel.)
- Published
- 2020
- Full Text
- View/download PDF
38. Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney disease.
- Author
-
Rossing P, Block GA, Chin MP, Goldsberry A, Heerspink HJL, McCullough PA, Meyer CJ, Packham D, Pergola PE, Spinowitz B, Sprague SM, Warnock DG, and Chertow GM
- Subjects
- Adult, Albuminuria drug therapy, Albuminuria etiology, Diabetes Mellitus, Type 2 urine, Diabetic Nephropathies etiology, Diabetic Nephropathies urine, Double-Blind Method, Early Termination of Clinical Trials, Female, Glomerular Filtration Rate drug effects, Heart Failure chemically induced, Heart Failure epidemiology, Humans, Kidney Failure, Chronic etiology, Kidney Failure, Chronic urine, Male, Middle Aged, Oleanolic Acid administration & dosage, Oleanolic Acid adverse effects, Treatment Outcome, Albuminuria diagnosis, Creatinine urine, Diabetes Mellitus, Type 2 complications, Diabetic Nephropathies drug therapy, Kidney Failure, Chronic drug therapy, Oleanolic Acid analogs & derivatives
- Abstract
Bardoxolone methyl attenuates inflammation by inducing nuclear factor erythroid-derived 2-related factor 2 and suppressing nuclear factor κB. The Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes (BEACON) trial was a phase 3 placebo-controlled, randomized, double-blind, parallel-group, international, multicenter trial in 2185 patients with type 2 diabetes mellitus and stage 4 chronic kidney disease. BEACON was terminated because of safety concerns, largely related to a significant increase in early heart failure events in patients randomized to bardoxolone methyl. Bardoxolone methyl resulted in increased estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio. Herein, we present post hoc analyses characterizing the relation between the urine albumin-to-creatinine ratio and eGFR. The urine albumin-to-creatinine ratio and eGFR were assessed every four weeks through Week 12, followed by assessments every eight weeks thereafter, and 4 weeks after the last dose of bardoxolone methyl was administered. The initial increases in urine albumin-to-creatinine ratio observed in patients randomized to bardoxolone methyl were attenuated after six months. Multivariable regression analysis identified baseline eGFR and eGFR over time as the dominant factors associated with change in the urine albumin-to-creatinine ratio. Relative to placebo, bardoxolone methyl resulted in a significant decrease in albuminuria when indexed to eGFR (least-squared means: -0.035 [95% confidence interval -0.031 to -0.039]). Thus, among patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl, changes in albuminuria are directly related to changes in eGFR, challenging the conventional construct that increases in albuminuria universally reflect kidney injury and denote harm., (Copyright © 2019 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
39. Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease-mineral bone disorder parameters in dialysis patients.
- Author
-
Ketteler M, Sprague SM, Covic AC, Rastogi A, Spinowitz B, Rakov V, Walpen S, and Floege J
- Subjects
- Chelating Agents therapeutic use, Chronic Kidney Disease-Mineral and Bone Disorder complications, Chronic Kidney Disease-Mineral and Bone Disorder metabolism, Drug Combinations, Female, Fibroblast Growth Factor-23, Follow-Up Studies, Humans, Hyperphosphatemia etiology, Male, Middle Aged, Parathyroid Hormone blood, Phosphorus blood, Time Factors, Treatment Outcome, Chronic Kidney Disease-Mineral and Bone Disorder therapy, Ferric Compounds therapeutic use, Hyperphosphatemia drug therapy, Renal Dialysis, Sevelamer therapeutic use, Sucrose therapeutic use
- Abstract
Background: Treatment of hyperphosphataemia is the primary goal of chronic kidney disease-mineral and bone disorder (CKD-MBD) management. This post hoc analysis of a randomized, Phase 3 study evaluated the effects of 1-year treatment with the phosphate binders sucroferric oxyhydroxide or sevelamer carbonate ('sevelamer') on CKD-MBD indices among dialysis patients with hyperphosphataemia., Methods: After a 2- to 4-week washout from previous phosphate binders, 1059 patients were randomized 2:1 to sucroferric oxyhydroxide 1.0-3.0 g/day (n = 710) or sevelamer 2.4-14.4 g/day (n = 349) for up to 24 weeks. Eligible patients enrolled in a 28-week extension. This post hoc analysis was performed for patients who completed ≥1 year of continuous treatment (n = 549). As the treatment groups showed similar CKD-MBD outcomes, the data were pooled for this analysis., Results: Phosphate-binder therapy was associated with significant and sustained 30% reductions in serum phosphorus (P < 0.001). Median intact fibroblast growth factor-23 (FGF-23) also significantly decreased (P < 0.001) by 64% over 1 year. Intact parathyroid hormone decreased significantly after 24 weeks (P < 0.001), but levels returned to near baseline values by Week 52; minimal changes in serum calcium were observed. Of the bone resorption markers evaluated, tartrate-resistant acid phosphatase 5b (TRAP5b) decreased significantly (P < 0.001), whereas CTx increased transiently but returned to baseline levels by Week 52. The bone formation markers bone-specific alkaline phosphatase and osteocalcin both increased over 1 year of treatment., Conclusions: Overall, 1 year of sucroferric oxyhydroxide or sevelamer treatment significantly reduced serum FGF-23, which has been associated with clinical benefit in patients with CKD. The trend towards increased bone formation marker levels indicates a beneficial effect on bone metabolism., (© The Author(s) 2018. Published by Oxford University Press on behalf of ERA-EDTA.)
- Published
- 2019
- Full Text
- View/download PDF
40. Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE Trial.
- Author
-
Ix JH, Isakova T, Larive B, Raphael KL, Raj DS, Cheung AK, Sprague SM, Fried LF, Gassman JJ, Middleton JP, Flessner MF, Block GA, and Wolf M
- Subjects
- Adult, Double-Blind Method, Female, Fibroblast Growth Factor-23, Fibroblast Growth Factors drug effects, Glomerular Filtration Rate drug effects, Humans, Male, Middle Aged, Monte Carlo Method, Renal Insufficiency, Chronic blood, Risk Assessment, Severity of Illness Index, Treatment Outcome, Fibroblast Growth Factors blood, Lanthanum administration & dosage, Niacinamide administration & dosage, Phosphates blood, Renal Insufficiency, Chronic diagnosis, Renal Insufficiency, Chronic drug therapy
- Abstract
Background: Higher serum phosphate and fibroblast growth factor-23 (FGF23) levels may be modifiable to prevent cardiovascular disease in CKD. Short-term studies have reported modest efficacy in phosphate and FGF23 reduction with intestinal phosphate binders in CKD., Methods: To investigate effects of lanthanum carbonate (LC; a phosphate binder) and/or nicotinamide (NAM; an inhibitor of active intestinal phosphate transport) on serum phosphate and FGF23 in stage 3b/4 CKD, we conducted a randomized trial among individuals with eGFR 20-45 ml/min per 1.73 m
2 to NAM (750 mg twice daily) plus LC (1000 mg thrice daily), NAM plus LC placebo, LC plus NAM placebo, or double placebo for 12 months. Dual primary end points were change from baseline in serum phosphate and intact FGF23 concentrations., Results: Mean eGFR for the 205 participants was 32ml/min per 1.73 m2 . At baseline, serum phosphate was 3.7 mg/dl and median FGF23 was 99 pg/ml (10th, 90th percentiles: 59, 205). Mean rates of change in phosphate increased slightly over 12 months in all groups and did not differ significantly across arms. Similarly, percent changes in FGF23 per 12 months increased for all arms except LC plus placebo, and did not differ significantly across arms. Gastrointestinal symptoms limited adherence. Adverse events rates were similar across arms., Conclusions: LC and/or NAM treatment did not significantly lower serum phosphate or FGF23 in stage 3b/4 CKD over 12 months. Although these agents appeared safe, intestinal symptoms limited adherence. Reducing phosphate and FGF23 in nondialysis CKD will require new approaches., (Copyright © 2019 by the American Society of Nephrology.)- Published
- 2019
- Full Text
- View/download PDF
41. Rationale for Raising Current Clinical Practice Guideline Target for Serum 25-Hydroxyvitamin D in Chronic Kidney Disease.
- Author
-
Strugnell SA, Sprague SM, Ashfaq A, Petkovich M, and Bishop CW
- Subjects
- Aged, Double-Blind Method, Drug Monitoring standards, Female, Fibroblast Growth Factor-23, Humans, Hyperparathyroidism, Secondary blood, Hyperparathyroidism, Secondary diagnosis, Hyperparathyroidism, Secondary etiology, Male, Middle Aged, Parathyroid Hormone blood, Practice Guidelines as Topic, Reference Values, Renal Insufficiency, Chronic blood, Vitamin D blood, Vitamin D Deficiency blood, Vitamin D Deficiency diagnosis, Vitamin D Deficiency etiology, Calcifediol administration & dosage, Hyperparathyroidism, Secondary drug therapy, Renal Insufficiency, Chronic complications, Vitamin D analogs & derivatives, Vitamin D Deficiency drug therapy
- Abstract
Background: Vitamin D repletion is recommended for secondary hyperparathyroidism (SHPT) and associated vitamin D insufficiency (VDI) in chronic kidney disease (CKD), but optimal levels of serum total 25-hydroxyvitamin D remain undefined. Clinical practice guidelines target sufficiency, whereas recent data indicate that higher levels are required to control the elevation of intact parathyroid hormone (iPTH) as CKD advances. This secondary analysis of 2 randomized controlled trials seeks to identify the minimum level of mean serum 25-hydroxyvitamin D required to control SHPT arising from VDI in stage 3 or 4 CKD., Methods: Adult subjects (n = 429) with SHPT, VDI, and stage 3 or 4 CKD were stratified by stage and treated daily with either extended-release calcifediol (ERC) or placebo in 2 identical, parallel, randomized, double-blind studies. After treatment for 26 weeks, all subjects were ranked by the level of serum total 25-hydroxyvitamin D and divided into quintiles in order to examine the relationships between the degree of vitamin D repletion and the associated changes in plasma iPTH, serum bone turnover markers, calcium, phosphorus, intact fibroblast growth factor 23 (FGF23) and vitamin D metabolites, estimated glomerular filtration rate (eGFR), and urine calcium:creatinine (Ca:Cr) ratio., Results: Progressive increases in serum 1,25-dihydroxyvitamin D and reductions in plasma iPTH and serum bone turnover markers were observed as mean posttreatment serum 25-hydroxyvitamin D rose from 13.9 ng/mL (in Quintile 1) to 92.5 ng/mL (in Quintile 5), irrespective of CKD stage. Mean serum calcium, phosphorus and FGF23, eGFR, and urine Ca:Cr ratio (collectively "safety parameters") did not significantly change from Quintile 1. Suppression of iPTH and bone turnover markers was not observed until serum 25-hydroxyvitamin D rose to at least 50.8 ng/mL (Quintile 3)., Conclusion: ERC therapy produced exposure-dependent reductions in plasma iPTH and bone turnover markers only when mean serum total 25-hydroxyvitamin D reached at least 50.8 ng/mL, indicating that current targets for vitamin D repletion therapy in CKD are too low. Gradual elevation of mean serum 25-hydroxyvitamin D to 92.5 ng/mL was not associated with significant adverse changes in safety parameters., (© 2019 S. Karger AG, Basel.)
- Published
- 2019
- Full Text
- View/download PDF
42. Cortical Perfusion and Tubular Function as Evaluated by Magnetic Resonance Imaging Correlates with Annual Loss in Renal Function in Moderate Chronic Kidney Disease.
- Author
-
Prasad PV, Li LP, Thacker JM, Li W, Hack B, Kohn O, and Sprague SM
- Subjects
- Aged, Cell Hypoxia, Diffusion Magnetic Resonance Imaging, Disease Progression, Female, Furosemide administration & dosage, Glomerular Filtration Rate drug effects, Humans, Kidney Cortex diagnostic imaging, Kidney Tubules diagnostic imaging, Kidney Tubules drug effects, Magnetic Resonance Angiography, Male, Middle Aged, Oxygen blood, Oxygen Consumption physiology, Renal Insufficiency, Chronic blood, Renal Insufficiency, Chronic diagnostic imaging, Renal Insufficiency, Chronic drug therapy, Glomerular Filtration Rate physiology, Kidney Cortex blood supply, Kidney Tubules physiopathology, Renal Insufficiency, Chronic physiopathology
- Abstract
Background: Chronic hypoxia is a well-recognized factor in the pathogenesis of chronic kidney disease (CKD). Loss of microcirculation is thought to lead to enhanced renal hypoxia, which in turn results in the development of fibrosis, a hallmark of progressive CKD. To evaluate the role of functional magnetic resonance imaging (MRI), we performed perfusion, oxygenation, and diffusion MRI measurements in individuals with diabetes and stage 3 CKD., Methods: Fifty-four subjects (41 individuals with diabetes and stage 3 CKD and 13 healthy controls) participated in this study. Data with blood oxygenation level dependent (BOLD), arterial spin labeling perfusion and diffusion MRI were acquired using a 3T scanner., Results: Renal cortical perfusion was reduced in CKD compared to the controls (109.54 ± 25.38 vs. 203.17 ± 27.47 mL/min/100 g; p < 0.001). Cortical apparent diffusion coefficient showed no significant reduction in CKD compared to controls (1,596.10 ± 196.64 vs. 1,668.72 ± 77.29 × 10-6 mm2/s; p = 0.45) but was significantly associated with perfusion. Cortical R2* values were modestly increased in CKD (20.76 ± 4.08 vs. 18.74 ± 2.37 s-1; p = 0.12). Within the CKD group, R2*_Medulla and R2*_Kidney were moderately and negatively associated with estimated glomerular filtration rate. There was a significant association between cortical perfusion and medullary response to furosemide with annual loss of renal function, used as an estimate of CKD progression., Conclusions: Subjects with a moderate degree of CKD had significantly lower renal perfusion. Diffusion and BOLD MRI showed more modest differences between the groups. Individuals with progressive CKD had lower perfusion and response to furosemide., (© 2019 S. Karger AG, Basel.)
- Published
- 2019
- Full Text
- View/download PDF
43. Effects of bardoxolone methyl on body weight, waist circumference and glycemic control in obese patients with type 2 diabetes mellitus and stage 4 chronic kidney disease.
- Author
-
Chertow GM, Appel GB, Block GA, Chin MP, Coyne DW, Goldsberry A, Kalantar-Zadeh K, Meyer CJ, Molitch ME, Pergola PE, Raskin P, Silva AL, Spinowitz B, Sprague SM, and Rossing P
- Subjects
- Aged, Blood Glucose metabolism, Diabetes Mellitus, Type 2 blood, Diabetes Mellitus, Type 2 complications, Diabetic Nephropathies blood, Diabetic Nephropathies drug therapy, Diabetic Nephropathies pathology, Disease Progression, Double-Blind Method, Female, Glomerular Filtration Rate drug effects, Glycated Hemoglobin drug effects, Glycated Hemoglobin metabolism, Humans, Male, Middle Aged, Obesity blood, Obesity complications, Oleanolic Acid pharmacology, Oleanolic Acid therapeutic use, Renal Insufficiency, Chronic blood, Renal Insufficiency, Chronic pathology, Blood Glucose drug effects, Body Weight drug effects, Diabetes Mellitus, Type 2 drug therapy, Obesity drug therapy, Oleanolic Acid analogs & derivatives, Renal Insufficiency, Chronic drug therapy, Waist Circumference drug effects
- Abstract
Aims: Obesity is associated with progression of chronic kidney disease (CKD). Treatment with bardoxolone methyl in a multinational phase 3 trial, Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes (BEACON), resulted in increases in estimated glomerular filtration rate (eGFR) with concurrent reductions in body weight. We performed post-hoc analyses to further characterize reductions in body weight with bardoxolone methyl., Methods: Eligible patients with type 2 diabetes (T2DM) and CKD stage 4 (eGFR 15 to <30 mL/min/1.73 m
2 ) were randomized 1:1 to receive once-daily oral dose of bardoxolone methyl (20 mg) or placebo., Results: BEACON enrolled 2185 patients. Patients randomized to bardoxolone methyl experienced significant reductions in body weight from baseline relative to patients randomized to placebo (-5.7 kg; 95% CI: -6.0 to -5.3 kg; p < 0.001). In patients randomized to bardoxolone methyl, rate and magnitude of body weight loss were proportional to baseline BMI. Bardoxolone methyl resulted in significant reductions in waist circumference and improved glycemic control., Conclusions: Bardoxolone methyl resulted in significant weight loss in a generally obese patient population with T2DM and stage 4 CKD, with the magnitude and rate dependent on baseline BMI., (Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.)- Published
- 2018
- Full Text
- View/download PDF
44. Mineral and Bone Disease in Kidney Transplant Recipients.
- Author
-
Altman AM and Sprague SM
- Subjects
- Bone Density, Bone Diseases, Metabolic metabolism, Humans, Kidney Failure, Chronic surgery, Bone Diseases, Metabolic etiology, Kidney Transplantation adverse effects, Minerals metabolism, Transplant Recipients
- Abstract
Purpose of Review: Despite metabolic improvements following kidney transplantation, transplant recipients still often suffer from complex mineral and bone disease after transplantation., Recent Findings: The pathophysiology of post-transplant disease is unique, secondary to underlying pre-transplant mineral and bone disease, immunosuppression, and changing kidney function. Changes in modern immunosuppression regimens continue to alter the clinical picture. Modern management includes reducing cumulative steroid exposure and correcting the biochemical abnormalities in mineral metabolism. While bone mineral density screening appears to help predict fracture risk and anti-osteoporotic therapy appears to have a positive effect on bone mineral density, more data regarding specific treatment is necessary. Patients with mineral and bone disease after kidney transplantation require special care in order to properly manage and mitigate their mineral and bone disease. Recent changes in clinical management of transplant patients may also be changing the implications on patients' mineral and bone disease.
- Published
- 2018
- Full Text
- View/download PDF
45. Long-term efficacy and safety of sucroferric oxyhydroxide in African American dialysis patients.
- Author
-
Sprague SM, Ketteler M, Covic AC, Floege J, Rakov V, Walpen S, and Rastogi A
- Subjects
- Black or African American, Drug Combinations, Female, Ferric Compounds pharmacology, Humans, Male, Middle Aged, Sucrose pharmacology, Ferric Compounds therapeutic use, Renal Dialysis methods, Sucrose therapeutic use
- Abstract
Introduction: Sucroferric oxyhydroxide (SFOH) is a non-calcium, iron-based phosphate binder that demonstrated sustained serum phosphorus (sP) control, good tolerability, and lower pill burden, vs. sevelamer carbonate ("sevelamer"), in a Phase 3 study conducted in dialysis patients with hyperphosphatemia. This analysis evaluates the efficacy and safety of SFOH and sevelamer among African American (AA) patients participating in the trial., Methods: Post hoc analysis of a 24-week, Phase 3, open-label trial (NCT01324128) and its 28-week extension study (NCT01464190). Patients were randomized 2:1 to SFOH (1.0-3.0 g/day) or sevelamer (2.4-14.4 g/day) for up to 52 weeks., Findings: Of 549 patients who completed the Phase 3 study and extension, 100 (18.2%) AA patients were eligible for efficacy analysis (SFOH, n = 48; sevelamer, n = 52). sP concentrations decreased rapidly and comparably with both treatments by Week 8 (mean ± standard deviation change from baseline: -1.9 ± 1.9 mg/dL for SFOH and -2.2 ± 1.8 mg/dL for sevelamer). These reductions were maintained for 52 weeks (-2.1 ± 2.6 and -2.1 ± 1.6 mg/dL) and achieved with a lower mean pill burden (3.4 ± 1.4 vs. 7.6 ± 2.9 tablets/day) with SFOH vs. sevelamer. Treatment adherence rates (adherence within 70%-120% of expected medication intake) were 79.2% with SFOH and 59.6% with sevelamer. The proportion of patients reporting serious adverse events (AEs) was 27.7% with SFOH and 30.7% with sevelamer. More patients withdrew due to treatment-emergent AEs with SFOH vs. sevelamer (18.5% vs. 8.0%). The most common AEs with both treatments were gastrointestinal-related: diarrhea and discolored feces with SFOH, and nausea, vomiting, and constipation with sevelamer., Discussion: SFOH is an efficacious and well-tolerated treatment for hyperphosphatemia in AA dialysis patients, with a lower pill burden and an improved adherence rate vs. sevelamer. These findings were consistent with the wider US patient population and the overall study population., (© 2018 The Authors Hemodialysis International published by Wiley Periodicals, Inc. on behalf of International Society for Hemodialysis.)
- Published
- 2018
- Full Text
- View/download PDF
46. Multicenter Study Evaluating Intrarenal Oxygenation and Fibrosis Using Magnetic Resonance Imaging in Individuals With Advanced CKD.
- Author
-
Prasad PV, Li W, Raj DS, Carr J, Carr M, Thacker J, Li LP, Wang C, Sprague SM, Ix JH, Chonchol M, Block G, Cheung AK, Raphael K, Gassman J, Wolf M, Fried LF, and Isakova T
- Published
- 2018
- Full Text
- View/download PDF
47. Sucroferric oxyhydroxide for the treatment of hyperphosphatemia.
- Author
-
Sprague SM and Floege J
- Subjects
- Chelating Agents therapeutic use, Clinical Trials as Topic, Drug Combinations, Ferric Compounds chemistry, Ferric Compounds pharmacokinetics, Government Regulation, Humans, Hyperphosphatemia complications, Phosphates blood, Renal Dialysis, Renal Insufficiency, Chronic complications, Renal Insufficiency, Chronic pathology, Sucrose chemistry, Sucrose pharmacokinetics, Treatment Outcome, Ferric Compounds therapeutic use, Hyperphosphatemia drug therapy, Sucrose therapeutic use
- Abstract
Introduction: Sucroferric oxyhydroxide is a non-calcium, iron-based phosphate binder indicated for the treatment of hyperphosphatemia in patients with chronic kidney disease undergoing dialysis. Areas covered: Herein, the preclinical development and clinical data for sucroferric oxyhydroxide are reviewed, including the key data from the Phase III registration study and the latest evidence from the real-world clinical setting. Expert opinion: Sucroferric oxyhydroxide displays potent phosphate-binding capacity and clinical studies demonstrate its effectiveness for the long-term reduction of serum phosphorus levels in dialysis patients. Observational study data also show that sucroferric oxyhydroxide provides effective serum phosphorus control for hyperphosphatemic patients in the real-world clinical setting. The serum phosphorus reductions with sucroferric oxyhydroxide can be achieved with a relatively low pill burden in comparison with other phosphate binders, which may translate into better treatment adherence in clinical practice. The Phase III data also indicate that sucroferric oxyhydroxide has a favorable impact on other chronic kidney disease-related mineral bone disease parameters, including a fibroblast growth factor-23-lowering effect. Sucroferric oxyhydroxide is well tolerated and associated with low systemic iron absorption, minimizing the potential for iron accumulation or overload. These attributes render sucroferric oxyhydroxide an attractive non-calcium-containing phosphate binder for the treatment of hyperphosphatemia.
- Published
- 2018
- Full Text
- View/download PDF
48. Should phosphate management be limited to the KDIGO/ KDOQI guidelines?
- Author
-
Dhillon-Jhattu S and Sprague SM
- Subjects
- Fibroblast Growth Factor-23, Guideline Adherence, Humans, Hyperphosphatemia diagnosis, Hyperphosphatemia etiology, Practice Guidelines as Topic, Renal Insufficiency, Chronic therapy, Risk Assessment, Hyperphosphatemia therapy, Renal Dialysis, Renal Insufficiency, Chronic complications
- Abstract
Hyperphosphatemia is a common complication of CKD. Prior to development of overt hyperphosphatemia, there are several adaptive mechanisms that occur to maintain normal phosphorus equilibrium in patients with CKD. These include an early and progressive rise in fibroblast growth factor 23 (FGF 23), followed by an increase in parathyroid hormone (PTH) with a decrease in 1,25-dihydroxyvitamin D (1,25 Vit D). Over the last 20 years, a large number of studies have shown that hyperphosphatemia is a strong predictor of adverse clinical outcomes including increased incidence of vascular calcification, cardiovascular disease, and all-cause mortality in both individuals with CKD as well as those with normal kidney function. In addition, elevations of both FGF 23 and PTH are independently associated with increased morbidity and mortality. Therefore, phosphorus lowering therapies are a vital part of the treatment strategy for patients with CKD and include dietary phosphorus restriction, treatment with phosphate binders and removal with dialysis. However, there has been a lack of high quality evidence demonstrating beneficial effects of phosphate lowering therapy on clinical outcomes. Furthermore, we do not have definitive data as to whether effective phosphate control with phosphate binders will prevent elevations in FGF 23, and whether lowering FGF 23 levels will lead to improved patient outcomes. As a result of the presently available data (or lack thereof) clinical guidelines recommend treatment only after hyperphosphatemia develops and in dialysis patients; KDOQI recommends a treatment target of less than 5.5 mg/dL, whereas KDIGO recommends treating "towards normal." We are left with a clinical dilemma, being whether these recommendations are adequate, or should we be more aggressive in phosphate management. In this article, our goal is to discuss some of the studies concerning the adverse consequences of phosphate excess and as well as elevated FGF 23 levels, and present our opinion on what we believe the goal of treatment should be., (© 2018 Wiley Periodicals, Inc.)
- Published
- 2018
- Full Text
- View/download PDF
49. One-year efficacy and safety of the iron-based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis.
- Author
-
Floege J, Covic AC, Ketteler M, Mann J, Rastogi A, Spinowitz B, Rakov V, Lisk LJ, and Sprague SM
- Subjects
- Adult, Aged, Combined Modality Therapy, Drug Combinations, Female, Ferric Compounds adverse effects, Humans, Hyperphosphatemia blood, Hyperphosphatemia etiology, Male, Medication Adherence, Middle Aged, Peritoneal Dialysis, Phosphates blood, Sucrose adverse effects, Treatment Outcome, Ferric Compounds therapeutic use, Hyperphosphatemia drug therapy, Sucrose therapeutic use
- Abstract
Background: Sucroferric oxyhydroxide is a noncalcium, iron-based phosphate binder that demonstrated sustained serum phosphorus control, good tolerability and lower pill burden compared with sevelamer carbonate (sevelamer) in a Phase 3 study conducted in dialysis patients. This subanalysis examines the efficacy and tolerability of sucroferric oxyhydroxide and sevelamer in the peritoneal dialysis (PD) patient population., Methods: The initial study (NCT01324128) and its extension (NCT01464190) were multicenter, Phase 3, open-label, randomized (2:1), active-controlled trials comparing sucroferric oxyhydroxide (1.0-3.0 g/day) with sevelamer (2.4-14.4 g/day) in dialysis patients over 52 weeks in total., Results: In the overall study, 84/1055 (8.1%) patients received PD and were eligible for efficacy analysis (sucroferric oxyhydroxide, n = 56; sevelamer, n = 28). The two groups were broadly comparable to each other and to the overall study population. Serum phosphorus concentrations decreased comparably with both phosphate binders by week 12 (mean change from baseline - 0.6 mmol/L). Over 52 weeks, sucroferric oxyhydroxide effectively reduced serum phosphorus concentrations to a similar extent as sevelamer; 62.5% and 64.3% of patients, respectively, were below the Kidney Disease Outcomes Quality Initiative target range (≤1.78 mmol/L). This was achieved with a lower pill burden (3.4 ± 1.3 versus 8.1 ± 3.7 tablets/day) with sucroferric oxyhydroxide compared with sevelamer. Treatment adherence rates were 91.2% with sucroferric oxyhydroxide and 79.3% with sevelamer. The proportion of patients reporting at least one treatment-emergent adverse event was 86.0% with sucroferric oxyhydroxide and 93.1% with sevelamer. The most common adverse events with both treatments were gastrointestinal: diarrhea and discolored feces with sucroferric oxyhydroxide and nausea, vomiting and constipation with sevelamer., Conclusions: Sucroferric oxyhydroxide is noninferior to sevelamer for controlling serum phosphorus in patients undergoing PD, while providing a relatively low pill burden and a high rate of adherence., (© The Author 2017. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
50. Extended-release calcifediol for secondary hyperparathyroidism in stage 3-4 chronic kidney disease.
- Author
-
Sprague SM, Strugnell SA, and Bishop CW
- Abstract
Introduction: Extended-release calcifediol (ERC) 30 µg capsules were recently approved as Rayaldee® by the United States Food and Drug Administration (FDA) for the treatment of secondary hyperparathyroidism (SHPT) in adults with stage 3-4 (not 5) chronic kidney disease (CKD) and vitamin D insufficiency (serum total 25-hydroxyvitamin D < 30 ng/mL). Calcifediol is 25-hydroxyvitamin D
3 , a prohormone of calcitriol (1,25-dihydroxyvitamin D3 ), the endogenous active vitamin D hormone. ERC capsules have a lipophilic fill which gradually releases calcifediol, corrects vitamin D insufficiency and increases serum calcitriol and thereby suppresses production of parathyroid hormone (PTH) in CKD patients without perturbing normal vitamin D and mineral metabolism. Areas covered: This review focuses on the chemical, pharmacokinetic, pharmacodynamic and clinical profiles of ERC and describes the product's utility relative to other current treatment options for SHPT. Expert commentary: Randomized clinical trials (RCTs) have demonstrated that nutritional vitamin D is ineffective for treating SHPT whereas vitamin D receptor activators can correct elevated PTH but with increased risk of hypercalcemia and hyperphosphatemia. ERC offers healthcare professionals a new treatment option that has been demonstrated in RCTs to be safe and effective for controlling SHPT without meaningfully increasing serum concentrations of calcium or phosphorus.- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.